1Silverberg SJ,Walker MD,Bilezikian JP. Asymptomatic primary hyperparathyroidism[J].Journal of Clinical Densitometry,2013.14-21.
2Pradeep PV,Jayashree B,Mishra A,Mishra SK. Systematic review of primary hyperparathyroidism in India:the past,present,and the future trends[J].Int J Endocrinol,2011.921814.
3Bilezikian JP,Meng X,Shi Y,Silverberg SJ. Primary hyperpara-thyroidism in women:a tale of two cities--New York and Beijing[J].International Journal of Fertility and Women's Medicine,2000.158-165.
4Zhao L,Liu JM,He XY,Zhao HY Sun LH Tao B Zhang MJ Chen X Wang WQ Ning G. The changing clinical patterns of primary hyperparathyroidism in Chinese patients:data from 2000 to 2010 in a single clinical center[J].Journal of Clinical Endocrinology and Metabolism,2013.721-728.
5Silverberg SJ,Bilezikian JP. "Incipient" primary hyperparathyroi-dism:a "forme fruste" of an old disease[J].Journal of Clinical Endocrinology and Metabolism,2003.5348-5352.
6Lowe H,McMahon DJ,Rubin MR,Bilezikian JP Silverberg SJ. Normocalcemic primary hyperparathyroidism:further characteri-zation of a new clinical phenotype[J].Journal of Clinical Endocrinology and Metabolism,2007.3001-3005.
7Rao DS,Wilson RJ,Kleerekoper M,Parfitt AM. Lack of biochemi-cal progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism:evidence for bipha-sic disease course[J].Journal of Clinical Endocrinology and Metabolism,1988.1294-1298.
8Cusano NE,Maalouf NM,Wang PY,Zhang C,Cremers SC,Haney EM,Bauer DC,Orwoll ES,Bilezikian JP. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based non-referral populations[J].Journal of Clinical Endocrinology and Metabolism,2013.
9Eastell R,Arnold A,Brandi ML,Brown EM D'Amour P Hanley DA Rao DS Rubin MR Goltzman D Silverberg SJ Marx SJ Peacock M Mosekilde L Bouillon R Lewiecki EM. Diagnosis of asymptomatic primary hyperparathyroidism:proceedings of the third international workshop[J].Journal of Clinical Endocrinology and Metabolism,2009.340-350.
10Silverberg SJ,Lewiecki EM,Mosekilde L,Peacock M Rubin MR. Presentation of asymptomatic primary hyperparathyroidism:proceedings of the third international workshop[J].J Clin Endo-crinol Metab,2009.351-365.
2Eigelberer MS, Clark OH. Surgical approached to primaryhyperparathyroidism [ J ]. Endocrinal Metab Clin North Am,2000,29 (3): 479-502.
3AACE/AAES. Task Force on Primary Hyperparathyroidism. TheAmerican Association of Clinical Endocrinologists and the AmericanAssociation of Endocrine Surgeons position statement on the diagnosisand management of primary hyperparathyroidism [ J ]. Endocr -Pract, 2005, 11 (1) ; 49-54.
5Denham DW, Norman J. Cost - effectiveness of preoperative sestamibiscan for primary hyperparathyroidism is dependent solely upon thesurgeon choices of operative procedure [ J]. J Am Coll Surg,2008 ,186 (3): 293 -305.
6Hunt JL, Carty SE, Yim JH, et al. Allelic loss in parathyroidPathol, 2005,29 (8) : 1049 -1055.
7Ono H, Osanai T, Ishizaka H, et al. Nicorandil improves cardiacfunction and clinical outcomes in patients with acute myocardialinfarction undergoing primary percutaneous coronary intervention role ofinhibitory effect on reactive oxygen species formation [ J ]. Am HeartJ,2004, 148 (4); E15.
8Richard BF, Demay MB, Kronenberg A, et al. Hormones anddisorders of mineral metabolism [ J]. Endocrinology, 2008 , 50:1172 -1175.
9Coston SD,Pelton JJ. Success of cervical exploration for patients withasymptomatic primary hyperparathyroidism [ J] . Am J Surg, 1999,177 (1) : 69-74.
10Grant CS, Thompson G, Farley D, et al. Primary hyperparathyroidismsurgical management since the introduction of minimally invasiveparathyroidectomy: mayo clinic e)q)erience [J]. Arch Surge, 2005,140 (5) : 478 -479.
